Skip to main content
Clinical Trials/NCT02248467
NCT02248467
Completed
Not Applicable

Study of the Effect of Testosterone Replacement Therapy on Metabolic Parameters, Prostatic Inflammation Symptoms and Lower Urinary Tract Symptoms (LUTS) in Hypogonadal Obese Subjects Eligible for Bariatric Surgery.

University of Florence1 site in 1 country100 target enrollmentMay 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
University of Florence
Enrollment
100
Locations
1
Primary Endpoint
IPSS score (LUTS) improvement
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The primary purpose of the study is to evaluate, in obese and hypogonadal patients eligible for bariatric surgery, the effect of testosterone replacement therapy in improving lower urinary tract symptoms (LUTS) assessed using the IPSS (International Prostate Symptom Score) questionnaire, compared to hypogonadal untreated subjects and eugonadal subjects.

Detailed Description

Primary objective: - Evaluation in obese and hypogonadal patients candidates for bariatric surgery of the effect of testosterone replacement therapy in improving the symptoms of LUTS (assessed using the IPSS questionnaire) compared to hypogonadal untreated subjects and eugonadal subjects. Secondary objectives: * Evaluation of the effect of testosterone in obese and hypogonadal patients candidates for bariatric surgery in improving metabolic parameters (glycaemia, oral glucose tolerance test, HbA1c, total cholesterol, HDL cholesterol, triglycerides, arterial pressure, BMI, waist circumference) compared to hypogonadal untreated subjects and eugonadal subjects * Evaluation of the effect of testosterone in obese and hypogonadal patients candidates for bariatric surgery in improving uroflowmetric parameters compared to hypogonadal untreated subjects and eugonadal subjects * Evaluation of the effect of testosterone in obese and hypogonadal patients candidates for bariatric surgery on the ultrasound characteristics of the prostate (macro-calcifications, intraprostatic arterial velocity, volume of the prostate gland). * Evaluation of the effect of testosterone in obese and hypogonadal patients candidates for bariatric surgery on pre-adipocytes isolated from visceral adipose tissue samples collected during surgical procedures, as compared to hypogonadal untreated subjects and eugonadal subjects.

Registry
clinicaltrials.gov
Start Date
May 2013
End Date
June 2018
Last Updated
7 years ago
Study Type
Observational
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mario Maggi

Full Professor of Endocrinology

University of Florence

Eligibility Criteria

Inclusion Criteria

  • Male subjects
  • Age between 25 and 65 years
  • Obese men, candidate to a bariatric surgery (body mass index (BMI) is ≥40 kg/m2, or if their BMI is \>35 kg/m2 and they suffer from other life-threatening co-morbidities such as Type 2 Diabetes Mellitus, hypertension and cardiovascular disease)
  • Men with LUTS defined by: IPSS ≥
  • Evidence of a personally signed and dated informed consent

Exclusion Criteria

  • Bladder failure or Neurogenic bladder
  • LUT disease (Urethral stenosis, diverticula)
  • LUT surgery (Prostatectomy, bladder neck surgery, TURP)
  • Severe systemic disease
  • Previous or concomitant neoplasm
  • Unable to consistently and accurately complete the protocol
  • Abuse alcohol or drugs
  • Psychiatric disease

Outcomes

Primary Outcomes

IPSS score (LUTS) improvement

Time Frame: 1 yr after surgery

For each patient the presence of an improvement of LUTS, assessed by IPSS score, will be evaluated by calculating the difference between the scores of the IPSS questionnaire administered at V1 compared to that administered to V0, V2 as compared to V1, or V3 as compared to V2. The mean of this change will be then compared between different groups (eugonadal; untreated hypogonadal; treated hypogonadal)

Secondary Outcomes

  • Change in the number of prostatic macrocalcifications(1 yr after surgery)
  • Change in the peak of arterial velocity at the colour-doppler ultrasound of the prostate(1 yr after surgery)
  • Improvement of sexual function(1 yr after surgery)
  • Improvement of symptoms of hypogonadism(1 yr after surgery)
  • Preadipocyte dysfunction assessed in preadipocyte isolated from visceral adipose tissue obtained during bariatric surgery(1 yr after surgery)
  • Variations in histomorphometric and molecular parameters of hepatic tissue obtained during bariatric surgery(1 yr after surgery)
  • Presence of Metabolic Syndrome(1 yr after surgery)
  • Volumetric change of the prostate(1 yr after surgery)

Study Sites (1)

Loading locations...

Similar Trials